Overview

Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose is to determine bioavailability of Bazedoxifene/conjugated estrogen formulations for future testing purposes.
Phase:
Phase 1
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Bazedoxifene
Estrogens
Estrogens, Conjugated (USP)